Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

Next Previous
Trial Profile

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nilotinib (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Adenoid cystic carcinoma; Adrenal cancer; Adrenocortical carcinoma; Anal cancer; Appendiceal cancer; Basal cell cancer; Bone cancer; Breast cancer; Carcinoid tumour; Carcinoma; Cervical cancer; Cholangiocarcinoma; Chordoma; Colon cancer; Endometrial cancer; Extramammary Paget disease; Fibroma; Gallbladder cancer; Gastric cancer; Gastrointestinal cancer; Gastrointestinal stromal tumours; Gestational trophoblastic disease; Giant cell tumours; Haemangiosarcoma; Head and neck cancer; Lung cancer; Lymphoma; Malignant thymoma; Malignant-mesothelioma; Merkel cell carcinoma; Mesothelioma; Nasopharyngeal cancer; Nerve sheath neoplasms; Neuroblastoma; Neuroendocrine carcinoma; Neuroendocrine tumours; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Paraganglioma; Parathyroid cancer; Penile cancer; Peritoneal cancer; Perivascular epithelioid cell tumours; Phaeochromocytoma; Pituitary cancer; Prostate cancer; Rectal cancer; Renal cell carcinoma; Salivary gland cancer; Sarcoma; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Testicular cancer; Thyroid cancer; Tracheobronchial cancer; Trophoblastic tumour; Urogenital cancer; Vulvovaginal cancer
  • Focus Therapeutic Use
  • Acronyms RARE CANCER

Most Recent Events

  • 18 Apr 2025 Planned End Date changed from 8 Apr 2025 to 8 Apr 2026.
  • 18 Apr 2025 Planned primary completion date changed from 2 Apr 2025 to 2 Apr 2026.
  • 06 Aug 2024 Planned number of patients changed from 34 to 82.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top